David Sharp, MD
Urology · Fairbanks, AKNPI 1275720344
Payments from drug & device makers
What this record shows
This record is dominated by food and beverage: $3,846 of the $5,691 with a category attached, or 67.6%. 24 manufacturers reported payments, led by Teleflex LLC at 29.3% of the total. Reporting peaked in 2021 at $2,100 and has fallen 67.5% since, to $683 in 2025.
Across 111 payments — averaging $51.27 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Teleflex LLC$2K
- Boston Scientific$1K
- Intuitive Surgical$1K
- Urogen Pharma, Inc.$243
- Accord Healthcare, Inc.$210
- Bayer$172
- plus $1K from 18 others
Across 3 payments — averaging $8854.97 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Dendreon Pharmaceuticals LLC$17K
- Novartis$9K
What the payments were for
- Travel & lodging$1,84532%
- Food & beverage$3,84668%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Teleflex LLC | 18 | $1,666 |
| Boston Scientific | 24 | $1,162 |
| Intuitive Surgical | 12 | $1,130 |
| Urogen Pharma, Inc. | 6 | $243 |
| Accord Healthcare, Inc. | 3 | $210 |
| Bayer | 3 | $172 |
| Astellas Pharma US Inc | 9 | $167 |
| Endo USA, Inc. | 7 | $147 |
| 180 Medical, Inc. | 5 | $129 |
| Dornier Medtech America, Inc | 1 | $102 |
| Endo Pharmaceuticals Inc. | 5 | $93 |
| Olympus America Inc. | 2 | $86 |
| Johnson & Johnson(2 entities) | 3 | $83 |
| Antares Pharma, Inc. | 2 | $47 |
| Sumitomo Pharma America, Inc. | 2 | $37 |
| Urovant Sciences Inc | 1 | $31 |
| Dendreon Pharmaceuticals LLC | 1 | $30 |
| Convatec Inc. | 1 | $29 |
| Ambu Inc. | 1 | $24 |
| Covidien LP | 1 | $22 |
| Novartis | 1 | $22 |
| Myriad Genetic Laboratories, Inc. | 1 | $20 |
| AbbVie | 1 | $19 |
| E.r. Squibb & Sons, L.L.C. | 1 | $18 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- UroLift System$1,161
- Da Vinci Surgical System$779
- LithoVue$225
- JELMYTO$137
- Nubeqa$125
- CAMCEVI$125
- UroLift$103
- Moses 550 DFL$103
- Consumables & Accessories$102
How this compares
$5,691 in reported general payments places this provider in the 85th percentile of 28 urology providers in Alaska.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| MyrbetriqMirabegron | 32 | $21,985 |
| GemtesaVibegron | 63 | $21,665 |
| Tamsulosin Hcl | 172 | $2,790 |
| Finasteride | 54 | $1,005 |
| Solifenacin Succinate | 17 | $834 |
| Cephalexin | 24 | $248 |
| Phenazopyridine Hcl | 32 | $149 |
| Levofloxacin | 40 | $75 |
| Oxycodone-AcetaminophenOxycodone Hcl/Acetaminophen | 25 | $58 |
| Ciprofloxacin Hcl | 15 | $42 |
| Gabapentin | 12 | $33 |
| Sulfamethoxazole-TrimethoprimSulfamethoxazole/Trimethoprim | 15 | $21 |
| Oxycodone Hcl | 11 | $11 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Astellas Pharma US IncMyrbetriq | $167 | $21,98532 claims |
| Sumitomo Pharma America, Inc.Gemtesa | $37 | $21,66563 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 28 urology providers in Alaska.
Other urology in Fairbanks
- Tony NimehFairbanks$4K
- Max LevittFairbanks$4K
- Shannon SmithFairbanks$3K
- Joshua LoganAnchorage$16K
- William ClarkAnchorage$9K
- Elysia SpencerAnchorage$8K
- Andre GodetAnchorage$5K
- Bryan WilsonAnchorage$4K
- Doug ChoJber$4K
- Mariam MillerAnchorage$4K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.